Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
Phase of Trial: Phase IV
Latest Information Update: 20 Jun 2016
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms A-TRI-WEEK
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2013 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.